EGM
CMPX icon

Engineers Gate Manager’s Compass Therapeutics CMPX Stock Holding History

Engineers Gate Manager’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.7K Sell
26,335
-45,418
-63% -$134K ﹤0.01% 2124
2026
Q1 		$380K Buy
+71,753
New +$414K ﹤0.01% 1576

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Engineers Gate Manager's CMPX Position: Q2 2026 in Review

Engineers Gate Manager reduced its Compass Therapeutics (CMPX) stake by 63% in Q2 2026, selling an estimated $134K and leaving 26,335 shares worth $57.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2124.

Engineers Gate Manager first reported a position in CMPX in Q1 2026 and has held it in 2 quarters since. The position peaked at $380K in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Engineers Gate Manager held 26,335 shares of Compass Therapeutics worth $57.7K as of Q2 2026.
  • Engineers Gate Manager sold 45,418 Compass Therapeutics shares in Q2 2026, an estimated $134K.
  • Compass Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #2124 holding.
  • Engineers Gate Manager first reported a position in Compass Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Engineers Gate Manager's Compass Therapeutics position peaked at $380K in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.